Printer Friendly

Existence of HbF Enhancer Haplotypes at HBS1L-MYB Intergenic Region in Transfusion-Dependent Saudi [beta]-Thalassemia Patients.

1. Introduction

The most common hereditary hemolytic anemias are [beta]-thalassemia and sickle cell disease (SCD). [beta]-Thalassemia is characterized by absence or reduction of [beta]-globin chain synthesis, while SCD is characterized by the production of abnormal [beta]-globin chain. However, the pathophysiology of each disorder is different [1]. Both SCD and [beta]-thalassemia are prevalent in the Eastern Province of Saudi Arabia and are characterized by a wide range of phenotypic heterogeneity [2-7]. Fetal hemoglobin (HbF; [alpha]2[gamma]2) is a major genetic modifier of disease severity in SCD [8]. Elevated HbF can ameliorate the clinical and hematologic severity of the disease and persistently elevated HbF partially compensates for the lack of HbA in [beta]-thalassemia and also decreases [alpha]/[beta] chain imbalance and the consequent toxicity of unpaired [alpha]-globin chains [9]. In Saudi [beta]-thalassemia patients, a highly elevated level of HbF, ranging from 40 to 98%, has been observed [10].

Understanding the regulation of HBG ([gamma]-globin gene) expression is of both biological and clinical relevance [9]. A section of DNA locus that correlates with phenotypic variation is known as quantitative trait locus (QTL). The first identified QTL associated with an elevated HbF level was the -158 C>T, XmnI site (rs7482144), at the 5' to HBG2 [11]. In the same region, that is, SNP rs5006884 in olfactory receptor (OR) genes (OR51B5 and OR51B6), upstream of the [beta]-globin gene cluster has been reported to be associated with elevated HbF level in several populations. The rs2071348 in the [beta]-globin locus is also in tight linkage disequilibrium with rs7482144 (HBG2) and is associated with elevated HbF [12]. Two other QTLs, located in the HBS1LMYB intergenic region and in the BCL11A gene, are either directly involved in HbF gene silencing in adult life or in cell proliferation and differentiation [9, 13-15]. BCL11A (2p16.1), HBS1L-MYB (6q23.3) and HBG2 promoter regions account for approximately 10-50% of HbF variation depending on the population studied, with the remaining variance in HbF level unaccounted for, indicating that additional loci are involved [16]. More recently, a polymorphism in intron 9 of ANTXR1, a type 1 transmembrane protein and receptor for anthrax toxin, was found to be associated with elevated HbF in Saudi patients with the AI haplotype [17]. Therefore, the objective of this study was to determine the existence of known HbF enhancer loci, BCL11A, HBG, and HBS1LMYB polymorphisms, and their haplotypes, in transfusion-dependent Saudi [beta]-thalassemia patients.

2. Materials and Methods

This is a case control study conducted on 174 transfusion-dependent [beta]-thalassemia patients (age range 2 to 18 years; 93 males and 81 females) and 164 age and sex matched healthy controls from the Eastern Province of Saudi Arabia. All [beta]-thalassemia patients attending three major hospitals in the Eastern Province, namely, King Fahd Hospital of the University, Dammam; Maternity and Children's Hospital, Dammam; and King Fahd Hospital, Al-Ahssa, were requested to participate in the study. All the patients included in this study were clinically diagnosed with [beta]-thalassemia major. In addition, the [beta]-thalassemia mutations in the majority of these patients have been identified and reported previously [2, 7]. The HbF levels reported in this manuscript represent the first baseline measurement for these patients, who are transfused regularly every two to three weeks. The patients' mean hemoglobin was maintained at approximately above 7.0 g/dL. All the controls were randomly selected from the general population with no history or family history of [beta]-thalassemia or SCD and from the same area.

This study was approved by the Ethical Committee of the University of Dammam in accordance with the 1964 Helsinki Declaration and its later amendments. Signed written informed consent was obtained from all participants. Blood samples were collected in EDTA vacutainers and DNA was extracted using blood minikit (Qiagen, GmbH, Hilden, Germany). HbF levels were determined using Bio-Rad Variant II (Variant II [beta]-Thalassemia Short Program Recorder Kit, Hercules, CA 94547, USA). The patient cohort was subgrouped based on HbF level, with 106 patients having a HbF level > 40% and 68 patients having a HbF level < 40%. SNP genotyping was carried out by nuclease allelic discrimination assay with target-specific forward and reverse primers along with TaqMan probes (Applied Biosystems, Foster City, California, USA) labeled with ViC and FAM for each allele on the ABI 7500 real-time PCR system (Applied Biosystems, Foster City, California, USA) according to the manufacturer's instructions. Fourteen SNPs, namely, rs2071348, rs7482144, and rs5006884 (HBG2 promoter region), rs766432, rs11886868, rs4671393, and rs7557939 (BCL11A region), and rs28384513, rs9376090, rs9399137, rs4895441, rs9389269, rs9402686, and rs9494142 (HBS1L-MYB region), were studied. All the SNPs were tested for Hardy-Weinberg equilibrium (HWE). Chi square and odds ratio was determined by SPSS version 19 to evaluate allele association. Linkage disequilibrium (LD) test was carried out using HaploView 4.2 software program to identify the nonrandom association of these 14 SNPs. Haplotype blocks were constructed using HaploView 4.2 program [18]. Haplotypes associated with [beta]-thalassemia were inferred based on the partition-ligation approach through EM algorithm. A p value below 0.05 was considered significant for all statistical analyses.

3. Results

The mean of hemoglobin level, mean corpuscular volume, ferritin, and iron of the 174 transfusion-dependent [beta]-thalassemia patients were 7.89 [+ or -] 1.66 g/dL, 68.93 [+ or -] 9.31 fl, 3222 [+ or -] 2396 [micro]g/L, and 81.05 [+ or -] 70.39 [micro]mol/L, respectively. The range of HbF in patients' cohort was 1.4 to 99.4% (83.77 [+ or -] 23.78%). Only five patients were found to have HbF level below 10% (1.4% n = 1; 5.9% n = 1; 8.1% n = 1 and 9.8% n = 2). All other patients in the low HbF cohort had a value HbF of between 10-39.1%. From the total patient group, the HbF pretransfusion level was >40% in 106 patients. All patients are treated with Deferasirox (Exjade, Novartis Pharmaceuticals Ltd., UK) an orally administered iron chelation agent. From the study group, 53 patients had splenomegaly, 20 undergone splenectomy, and 18 had bone abnormalities.

The independent segregation genotype for all the SNPs in the control group was in agreement with the Hardy-Weinberg equilibrium. Standard allelic association analysis of the 14 SNPs tested in the patient cohort showed that only six SNPs in the HBS1L-MYB region, namely, rs9376090, rs9399137, rs4895441, rs9389269, rs9402686, and rs9494142, were significantly associated with [beta]-thalassemia. There were no significant differences in allele frequencies of SNPs in the HBG2 promoter region and BCL11A region between the [beta]-thalassemia and control groups (Table 1). However, when the patients were subgrouped into those who had HbF > 40% (106 patients) and those who had HbF < 40% (68 patients), the group with HbF > 40% showed a significant association with the six [beta]-thalassemia associated SNPs, in addition to two other SNPs, namely, rs7557939 (OR = 1.54, p = 0.013) and rs11886868 (OR = 1.47, p = 0.029) on BCL11A locus. The subgroup with HbF <40% showed only rs2071348 on HBG2 promoter region to be associated with [beta]-thalassemia (Table S1 in Supplementary Material available online at https://doi.org/10.1155/2017/1972429).

The predominant haplotypes in the whole [beta]-thalassemia cohort consisted of GTT and TCC in the HBG2 promoter region and GCCGCAC (p = 0.022; [chi square] = 5.257) in the HBS1L-MYB region (Figure 1). The CCGCAC (rs9376090C, rs9399137C, rs4895441G, rs9389269C, rs9402686A, and rs9494142C) haplotype pattern was the most significant HbF enhancer haplotype (p = 0.005; [chi square] = 7.739) followed by CTGCAC (p = 0.04; [chi square] = 4.181) (Table 2). The predominant haplotypes in the subgroup with HbF > 40% consisted of gTt in the HBG2 promoter region, ATGA in BCL11A, and GCCGCAC in the HBS1L-MYB region. The predominant haplotypes in the subgroup with HbF < 40% consisted of tCc in the HBG2 promoter region (Table S2).

4. Discussion

Human erythroid progenitor based functional studies revealed that reduced transcription factor bindings, which could affect long-range interactions with MYB due to common variants within the intergenic region (HBS1L-MYB), result in reduced MYB expression leading to elevated HbF levels [19]. In addition, common variants have been identified to be associated with elevated HbF in the BCL11A region and HBG2 promotor region in SCD [20]. The stimulation of HbF expression may provide alternative therapies for the amelioration of disease severity in [beta]-thalassemia and SCD [21]. Increased knowledge and understanding of the genetics of HbF regulation supports the development of innovative therapeutic targets, including the development of novel drug therapies.

To the best of our knowledge, this is the first study reporting the influence of 14 genetic markers spanning the three important QTLs, namely, HBG2 promoter, BCL11A, and HBS1L-MYB regions in [beta]-thalassemia major patients. In this study, we examined selected SNPs in the BCL11A, HBG2, and HBS1L-MYB loci on chromosomes 11p15.4, 2p16.1, and 6q23.3, respectively, in Saudi [beta]-thalassemia patients from the Eastern Province to determine their association with HbF levels. The selection of the SNPs was based on recently published studies, which reported that these genetic variants were most strongly associated with increased HbF levels in SCD and [beta]-thalassemia intermedia type of patients [9,20, 22-28].

Six of the 14 SNPs in the HBS1L-MYB region showed a strong association with [beta]-thalassemia. This is consistent with previous reports from European, Chinese and African [beta]-thalassemia intermedia and SCD patients [9, 13, 20, 22, 23, 25, 26, 28]. However, two of these SNPs (rs4895441 and rs93991370) did not show an association in SCD patients from the South-Western Province of Saudi Arabia [3]. It has to be noted that SCD in the Eastern Province carries the Arab-Indian haplotype, while in the South-Western Province, SCD patients carry the Benin haplotype [3].

The effects of BCL11A QTL on HbF levels have been reported in [beta]-thalassemia intermedia in different populations [29, 30]. In the present study, two SNPs, namely, rs7557939 and rs11886868, were found to be associated with [beta]-thalassemia in patients with HbF level > 40%. The other SNPs in the same region showed a lack of association with [beta]-thalassemia, in contrast to other studies conducted on Chinese and Portuguese populations [28, 31]. The lack of association with the transfusion-dependent [beta]-thalassemia major and association with the Hb E/[beta]-thalassemia cases [31] and beta-thalassemia carriers [28] suggests that rs4671393, rs7557939, and rs11886868 are HbF enhancer SNPs in [beta]-thalassemia intermedia.

It has been reported that the XmnI [sup.G][gamma]-7-158(C[right arrow]T) polymorphism (rs7482144) of HBG2 was associated with increased production of [sup.G][gamma] globin, and hence HbF can influence the heterogeneity of both blood transfusion-dependent and transfusion-independent [beta]-thalassemia patients [3237]. Although this SNP was reported to be associated with [beta]-thalassemia in a number of populations, in our cohort this association is lacking [24, 38]. Moreover, other SNPs (rs2071348 and rs5006884) in the HBG2 promoter region were shown to lack an association with [beta]-thalassemia in our cohort.

Haplotype analysis showed that CCGCAC in the HBS1LMYB region is strongly associated with [beta]-thalassemia in our cohort ([chi square] = 7.739; p = 0.005), while in the HBG2 region the haplotypes GTT ([chi square] = 6.767; p = 0.009) and TCC ([chi square] = 5.652; p = 0.017) showed a strong association with [beta]-thalassemia. Paucity of literature on the GTT haplotypes among [beta]-thalassemia prevents the comparison of their effect.

The haplotype analysis of present and previous studies of the SNPs from the three tested regions (HBG2 locus, BCL11A, and the HBS1L-MYB interregion) showed stronger association with elevated HbF level than single SNPs taken individually [15, 39]. Moreover, it has been shown that the distribution of BCL11A enhancer haplotypes showed significant differences based on geographical origin accounting for the HbF level deviation [40]. Interestingly, the ATGA haplotype formed from the four SNPs rs766432, rs11886868, rs4671393, and rs7557939, though it lacked an association with [beta]-thalassemia major. However, this haplotype was found to be associated with HbF in the subgroup of patients with HbF > 40%. This haplotype has been previously reported to be associated with elevated HbF in Saudi SCD patients from the Eastern Province [40].

5. Conclusion

The stimulation of HbF expression may provide alternative therapies for the amelioration of the disease severity of [beta]-thalassemia and SCD. Furthermore, increasing knowledge and understanding of the genetics of HbF regulation will support the development of innovative therapeutic targets, including the development of novel drug therapies. Therefore, our study provided valuable insights on the elements that influence elevated HbF levels in [beta]-thalassemia.

http://dx.doi.org/10.1155/2017/1972429

Competing Interests

The authors report no conflict of interests.

Authors' Contributions

Cyril Cyrus, Chittibabu Vatte, and Shahanas Chathoth designed the study, performed the assay, and drafted the manuscript. Zaki A. Nasserullah and Ahmed Sulaiman provided the [beta]-thalassemia patient samples; Hatem Qutub and Amein K. Al Ali provided the age and sex matched controls. Sana Al Jarrash and Hatem Qutub collected all medical data of the individual participant from the hospital records. J. Francis Borgio performed the HaploView analyses. Martin H. Steinberg and Alhusain J. Alzahrani were involved in drafting the manuscript for important intellectual content. Abdullah Al-Rubaish and Amein K. Al Ali provided critical review of the manuscript. All authors made significant intellectual contributions and have read and reviewed the manuscript. All authors read and approved the final manuscript. The authors alone are responsible for the content and writing of this article.

Acknowledgments

The authors thank King Abdulaziz City for Science and Technology for funding the project (to Dr. Cyril Cyrus, Grant no. LGP 31-34). They also thank Mr. Geoffrey James Tam Moro and Mr. Mohammed Al Shamlan for their technical and administrative support.

References

[1] K. I. Ataga, M. D. Cappellini, and E. A. Rachmilewitz, "[beta]-Thalassaemia and sickle cell anaemia as paradigms of hypercoagulability," British Journal of Haematology, vol. 139, no. 1, pp. 3-13, 2007.

[2] A. K. Al-Ali, S. Al-Ateeq, B. W. Imamwerdi et al., "Molecular bases of [beta]-thalassemia in the Eastern province of Saudi Arabia," Journal of Biomedicine and Biotechnology, vol. 2005, no. 4, pp. 322-325, 2005.

[3] A. Alsultan, N. Solovieff, A. Aleem et al., "Fetal hemoglobin in sickle cell anemia: Saudi patients from the Southwestern province have similar HBB haplotypes but higher HbF levels than African Americans," American Journal of Hematology, vol. 86, no. 7, pp. 612-614, 2011.

[4] M. S. Akhtar, F. Qaw, J. Francis Borgio et al., "Spectrum of a-thalassemia mutations in transfusion-dependent fithalassemia patients from the eastern province of Saudi Arabia," Hemoglobin, vol. 37, no. 1, pp. 65-73, 2013.

[5] J. F. Borgio, S. AbdulAzeez, A. N. Al-Nafie et al., "A novel HBA2gene conversion in cisor trans: '[alpha]12 allele' in a Saudi population," Blood Cells, Molecules, and Diseases, vol. 53, no. 4, pp. 199-203, 2014.

[6] A. N. Al-Nafie, J. F. Borgio, S. AbdulAzeez et al., "Coinheritance of novel ATRX gene mutation and globin ([alpha]&[beta]) gene mutations in transfusion dependent beta-thalassemia patients," Blood Cells, Molecules, and Diseases, vol. 55, no. 1, pp. 27-29, 2015.

[7] J. F. Borgio, S. AbdulAzeez, Z. A. Naserullah et al., "Mutations in the [beta]-globin gene from a Saudi population: an update," International Journal of Laboratory Hematology, vol. 38, no. 2, pp. e38-e40, 2016.

[8] D. A. Ngo and M. H. Steinberg, "Genomic approaches to identifying targets for treating hemoglobinopathies," BMC Medical Genomics, vol. 8, no. 1, article 44, 2015.

[9] M. Uda, R. Galanello, S. Sanna et al., "Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of [beta]-thalassemia," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 5, pp. 1620-1625, 2008.

[10] B. H. Al-Awamy, "Thalassemia syndromes in Saudi Arabia: meta-analysis of local studies," Saudi Medical Journal, vol. 21, no. 1, pp. 8-17, 2000.

[11] D. Labie, O. Dunda-Belkhodja, F. Rouabhi, J. Pagnier, A. Ragusa, and R. L. Nagel, "The -158 site 5' to the G gamma gene and G gamma expression," Blood, vol. 66, pp. 1463-1465, 1985.

[12] N. Solovieff, J. N. Milton, S. W. Hartley et al., "Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster," Blood, vol. 115, no. 9, pp. 1815-1822, 2010.

[13] S. Menzel, J. Jiang, N. Silver et al., "The HBS1L-MYB intergenic region on chromosome 6q23.3 influences erythrocyte, platelet, and monocyte counts in humans," Blood, vol. 110, no. 10, pp. 3624-3626, 2007.

[14] S. L. Thein, S. Menzel, X. Peng et al., "Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 27, pp. 11346-11351, 2007

[15] G. Galarneau, C. D. Palmer, V. G. Sankaran, S. H. Orkin, J. N. Hirschhorn, and G. Lettre, "Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation," Nature Genetics, vol. 42, no. 12, pp. 1049-1051, 2010.

[16] J. Borg, P. Papadopoulos, M. Georgitsi et al., "Haplo-insufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin," Nature Genetics, vol. 42, no. 9, pp. 801-807, 2010.

[17] V. Vinod, J. J. Farrell, S. Wang et al., "A candidate trans-acting modulator of fetal hemoglobin gene expression in the Arab-Indian haplotype of sickle cell anemia," American Journal of Hematology, vol. 91, no. 11, pp. 1118-1122, 2016.

[18] J. C. Barrett, B. Fry, J. Maller, and M. J. Daly, "Haploview: analysis and visualization of LD and haplotype maps," Bioinformatics, vol. 21, no. 2, pp. 263-265, 2005.

[19] R. Stadhouders, S. Aktuna, S. Thongjuea et al., "HBS1L-MYB intergenic variants modulate fetal hemoglobin via long-range MYB enhancers," The Journal of Clinical Investigation, vol. 124, no. 4, pp. 1699-1710, 2014.

[20] S. L. Thein, S. Menzel, M. Lathrop, and C. Garner, "Control of fetal hemoglobin: new insights emerging from genomics and clinical implications," Human Molecular Genetics, vol. 18, no. 2, pp. R216-R223, 2009.

[21] G. F. Atweh and D. Loukopoulos, "Pharmacological induction of fetal hemoglobin in sickle cell disease and [beta]-thalassemia," Seminars in Hematology, vol. 38, no. 4, pp. 367-373, 2001.

[22] G. Lettre, V. G. Sankaran, M. A. C. Bezerra et al., "DNA polymorphisms at the BCL11A, HBS1L-MYB, and fi-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 33, pp. 11869-11874, 2008.

[23] L. E. Creary, P. Ulug, S. Menzel et al., "Genetic variation on chromosome 6 influences F cell levels in healthy individuals of African descent and HbF levels in sickle cell patients," PLoS ONE, vol. 4, no. 1, Article ID e4218, 2009.

[24] T. K. T. Nguyen, P. Joly, C. Bardel, M. Moulsma, N. BonelloPalot, and A. Francina Alain, "The XmnI [sup.G][gamma] polymorphism influences hemoglobin F synthesis contrary to BCL11A and HBS1L-MYB SNPs in a cohort of 57 [beta]-thalassemia intermedia patients," Blood Cells, Molecules, and Diseases, vol. 45, no. 2, pp. 124-127, 2010.

[25] J. Makani, S. Menzel, S. Nkya et al., "Genetics of fetal hemoglobin in Tanzanian and British patients with sickle cell anemia," Blood, vol. 117, no. 4, pp. 1390-1392, 2011.

[26] J. J. Farrell, R. M. Sherva, Z.-Y. Chen et al., "A 3-bp deletion in the HBS1L-MYB intergenic region on chromosome 6q23 is associated with HbF expression," Blood, vol. 117, no. 18, pp. 4935-4945, 2011.

[27] G. L. Cardoso, I. G. Diniz, A. N. L. Martins da Silva et al., "DNA polymorphisms at BCL11A, HBS1L-MYB and Xmn1-HBG2 site loci associated with fetal hemoglobin levels in sickle cell anemia patients from Northern Brazil," Blood Cells, Molecules, and Diseases, vol. 53, no. 4, pp. 176-179, 2014.

[28] C. Pereira, L. Relvas, C. Bento, A. Abade, M. L. Ribeiro, and L. Manco, "Polymorphic variations influencing fetal hemoglobin levels: association study in beta-thalassemia carriers and in normal individuals of Portuguese origin," Blood Cells, Molecules, and Diseases, vol. 54, no. 4, pp. 315-320, 2015.

[29] S. Menzel, C. Garner, I. Gut et al., "A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15," Nature Genetics, vol. 39, no. 10, pp. 1197-1199, 2007.

[30] A. E. Sedgewick, N. Timofeev, P. Sebastiani et al., "BCL11Ais a major HbF quantitative trait locus in three different populations with fi-hemoglobinopathies," Blood Cells, Molecules, and Diseases, vol. 41, no. 3, pp. 255-258, 2008.

[31] Y. He, P. Chen, W. Lin, and J. Luo, "Analysis of rs4671393 polymorphism in hemoglobin E/[beta]-thalassemia major in guangxi province of China," Journal of Pediatric Hematology/Oncology, vol. 34, no. 4, pp. 323-324, 2012.

[32] S. L. Thein, J. S. Wainscoat, M. Sampietro et al., "Association of thalassaemia intermedia with a beta-globin gene haplotype," British Journal of Haematology, vol. 65, no. 3, pp. 367-373, 1987

[33] S. Fucharoen, N. Siritanaratkul, P. Winichagoon et al., "Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in [beta]-thalassemia/hemoglobin E disease," Blood, vol. 87, no. 3, pp. 887-892, 1996.

[34] G. V. Dedoussis, G. D. Mandilara, M. Boussiu et al., "HbF production in beta thalassaemia heterozygotes for the IVS-II1 G->A beta(0)-globin mutation Implication of the haplotype and the (G) gamma-158 C->T mutation on the HbF level," American Journal of Hematology, vol. 64, no. 3, pp. 151-155, 2000.

[35] M. Alebouyeh, F. Moussavi, H. Haddad-Deylami, and P. Vossough, "Hydroxyurea in the treatment of major [beta]-thalassemia and importance of genetic screening," Annals of Hematology, vol. 83, no. 7, pp. 430-433, 2004.

[36] N. F. Olivieri, G. M. Muraca, A. O'Donnell, A. Premawardhena, C. Fisher, and D. J. Weatherall, "Studies in haemoglobin E betathalassaemia," British Journal of Haematology, vol. 141, no. 3, pp. 388-397, 2008.

[37] L. Nuntakarn, S. Fucharoen, G. Fucharoen, K. Sanchaisuriya, A. Jetsrisuparb, and S. Wiangnon, "Molecular, hematological and clinical aspects of thalassemia major and thalassemia intermedia associated with Hb E-[beta]-thalassemia in Northeast Thailand," Blood Cells, Molecules, and Diseases, vol. 42, no. 1, pp. 32-35, 2009.

[38] P. Dabke, R. Colah, K. Ghosh, and A. Nadkarni, "Effect of cis acting potential regulators in the globin gene cluster on the production of HbF in thalassemia patients," The Mediterranean Journal of Hematology and Infectious Diseases, vol. 5, no. 1, Article ID e2013012, 2013.

[39] D. E. Bauer, S. C. Kamran, S. Lessard et al., "An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level," Science, vol. 342, no. 6155, pp. 253-257, 2013.

[40] P. Sebastiani, J. J. Farrell, A. Alsultan et al., "BCL11A enhancer haplotypes and fetal hemoglobin in sickle cell anemia," Blood Cells, Molecules, and Diseases, vol. 54, no. 3, pp. 224-230, 2015.

Cyril Cyrus, (1) Chittibabu Vatte, (1) J. Francis Borgio, (1) Abdullah Al-Rubaish, (2) Shahanas Chathoth, (1) Zaki A. Nasserullah, (3) Sana Al Jarrash, (3) Ahmed Sulaiman, (4) Hatem Qutub, (4) Hassan Alsaleem, (2) Alhusain J. Alzahrani, (5) Martin H. Steinberg, (6) and Amein K. Al Ali (2,4)

(1) Department of Genetic Research, Institute for Research and Medical Consultation, University of Dammam, Dammam, Saudi Arabia

(2) KingFahd Hospital of the University, University of Dammam, Dammam, Saudi Arabia

(3) Maternity and Children's Hospital, Dammam, Saudi Arabia

(4) Al-Omran Scientific Chair for Hematological Diseases, King Faisal University, Maternity and Children's Hospital, Dammam, Saudi Arabia

(5) College of Applied Medical Sciences, KingSaud University, Riyadh, Saudi Arabia

(6) Center of Excellence in Sickle Cell Disease, Department of Medicine, Boston University School of Medicine, Boston, MA, USA Correspondence should be addressed to Cyril Cyrus; ccyrus@uod.edu.sa

Received 9 October 2016; Revised 14 December 2016; Accepted 16 January 2017; Published 9 February 2017

Academic Editor: Milton O. Moraes

Caption: FIGURE 1: Linkage disequilibrium (LD) analysis patterns between 3 HBG2, 4 BCL11A, and 7 HBS1L-MYB SNPs compared in thalassemia patients against control cohort. The figure illustrates the chromosome 6 loci inhabiting the seven HBS1L-MYB interregion SNPs outlining the chromosomal location, SNP ID, and the positions that were genotyped in this study. HaploView output of LD across 14 SNPs from the genotyping data in Saudi population. The pairwise correlation between the SNPs was measured as [r.sup.2] and shown (x100) in each diamond. Enhancer haplotypes are in red boxes and diminisher haplotypes are in blue boxes. Coordinates are according to the NCBI build dbSNP 144 Homo sapiens annotation release 107 (reference sequence NT025741.16). Sig. SNPs: haplotypes of significant SNPs.
TABLE 1: Allelic association of 14 SNPs related to BCL11A,
HBS1L-MYB, and HBG2 promoter region in patients with
[beta]-thalassemia and controls.

SNP ID        Candidate gene     Chromosome position

rs2071348      HBG2 region           11:5242916
rs7482144      HBG2 region           11:5254939
rs5006884      HBG2 region           11:5352021
rs766432          BCL11A             2:60492835
rs11886868        BCL11A             2:60493111
rs4671393         BCL11A             2:60493816
rs7557939         BCL11A             2:60494212
rs28384513      HBS1L-MYB            6:135055071
rs9376090       HBS1L-MYB            6:135090090
rs9399137       HBS1L-MYB            6:135097880
rs4895441       HBS1L-MYB            6:135105435
rs9389269       HBS1L-MYB            6:135106021
rs9402686       HBS1L-MYB            6:135106679
rs9494142       HBS1L-MYB            6:135110502

SNP ID       Alleles (EA/OA)    [chi square]

rs2071348          t/g              1.184
rs7482144          c/t              0.498
rs5006884          t/c              1.222
rs766432           A/C                0
rs11886868         t/c              1.637
rs4671393          G/A              0.006
rs7557939          A/G              2.055
rs28384513         g/t              2.496
rs9376090          c/t              11.053
rs9399137          c/t              7.228
rs4895441          G/A              8.785
rs9389269          c/t              7.096
rs9402686          A/G              7.096
rs9494142          c/t              9.936

SNP ID       Case versus control    p value
             Odds ratio (95% CI)

rs2071348    0.832 (0.598-1.159)     0.277
rs7482144    0.881 (0.620-1.252)     0.480
rs5006884    0.818 (0.577-1.168)     0.269
rs766432     0.999 (0.719-1.388)     0.997
rs11886868   0.821 (0.607-1.111)     0.201
rs4671393    0.987 (0.709-1.375)     0.940
rs7557939    0.802 (0.592-1.085)     0.152
rs28384513   0.741 (0.511-1.075)     0.114
rs9376090    0.406 (0.235-0.700)     0.0009 *
rs9399137    0.473 (0.271-0.824)     0.008 *
rs4895441    0.449 (0.262-0.771)     0.004 *
rs9389269    0.495 (0.293-0.837)     0.008 *
rs9402686    0.495 (0.293-0.837)     0.008 *
rs9494142    0.459 (0.280-0.751)     0.002 *

* Significant association p values (p < 0.05)
for the allelic model. EA: effect allele tested for
association; OA: other allele;p: p value unadjusted;
chromosome position as per GRCh38.p2 Assembly.

TABLE 2: Frequency of haplotypes of SNPs in HBG2, BCL11A, and
HBS1L-MYB compared between patients with [beta]-thalassemia
and control cohorts.

Block         Candidate     Haplotype     Overall
                 gene                    frequency

             HBG2 region       TCC         0.574
             HBG2 region       GTT         0.119
1            HBG2 region       tct         0.114
             HBG2 region       gtc         0.108
             HBG2 region       GCC         0.064
             HBG2 region       ttc         0.016
                BCL11A         atga        0.516
2               BCL11A         CCAG        0.293
                BCL11A         ACGG         0.18
              HBS1L-MYB      tttatgt       0.725
              HBS1L-MYB      gttatgt       0.145
3             HBS1L-MYB      GCCGCAC       0.047
              HBS1L-MYB      tccgcac       0.031
              HBS1L-MYB      tttatgc       0.018
              HBS1L-MYB       ttatgt        0.87
Significant   HBS1L-MYB       CCGCAC       0.078
SNPs          HBS1L-MYB       ttatgc       0.018
              HBS1L-MYB       CTGCAC       0.012

Block         Candidate     Case versus control    [chi square]
                 gene         Case; control
                                frequencies

             HBG2 region       0.618, 0.528           5.652
             HBG2 region       0.150, 0.086           6.767
1            HBG2 region       0.103, 0.126           0.907
             HBG2 region       0.079, 0.138           6.136
             HBG2 region       0.044, 0.085           4.858
             HBG2 region       0.003, 0.029           7.306
                BCL11A         0.540, 0.491           1.648
2               BCL11A         0.290, 0.296           0.025
                BCL11A         0.158, 0.204           2.439
              HBS1L-MYB        0.692, 0.760           3.898
              HBS1L-MYB        0.139, 0.152           0.243
3             HBS1L-MYB        0.065, 0.028           5.257
              HBS1L-MYB        0.041, 0.021            2.25
              HBS1L-MYB        0.023, 0.012            1.13
              HBS1L-MYB        0.830, 0.912           9.837
Significant   HBS1L-MYB        0.106, 0.049           7.739
SNPs          HBS1L-MYB        0.023, 0.012            1.15
              HBS1L-MYB        0.020, 0.003           4.181

Block         Candidate        p value
                 gene

             HBG2 region    0.0174 ([phi])
             HBG2 region       0.0093 *
1            HBG2 region        0.3409
             HBG2 region    0.0132 ([phi])
             HBG2 region    0.0275 ([phi])
             HBG2 region    0.0069 ([phi])
                BCL11A          0.1992
2               BCL11A          0.8752
                BCL11A          0.1183
              HBS1L-MYB         0.0484
              HBS1L-MYB         0.6223
3             HBS1L-MYB        0.0219 *
              HBS1L-MYB         0.1336
              HBS1L-MYB         0.2877
              HBS1L-MYB     0.0017 ([phi])
Significant   HBS1L-MYB        0.0054 *
SNPs          HBS1L-MYB         0.2835
              HBS1L-MYB        0.0409 *

* Significant risk haplotypes (p < 0.05). Order of significant
SNPs: rs9376090, rs9399137, rs4895441, rs9389269, rs9402686,
and rs9494142. ([phi]) Haplotype associated with low HbF levels.
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Cyrus, Cyril; Vatte, Chittibabu; Borgio, J. Francis; Rubaish, Abdullah Al-; Chathoth, Shahanas; Nass
Publication:BioMed Research International
Geographic Code:7SAUD
Date:Jan 1, 2017
Words:4730
Previous Article:Numerical Method for the Design of Healing Chamber in Additive-Manufactured Dental Implants.
Next Article:The Neuroprotective Effects of Muscle-Derived Stem Cells via Brain-Derived Neurotrophic Factor in Spinal Cord Injury Model.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters